Joji Suzuki, director of addiction psychiatry at Brigham and Womens Hospital in Boston, who is leading two clinical trials of GLP-1s for alcohol and opioid use disorders and is not involved in the Providence program

oz.) Water/Aqua/Eau, C12-15 Alkyl Benzoate, Caprylic/Capric Triglyceride, Dicaprylyl Carbonate, Propanediol, Shea Butter Ethyl Esters, Glycerin, Cetearyl Alcohol, Behenyl Alcohol, Bentonite, Glyceryl Stearate, Hydrogenated Vegetable Glycerides, PEG-100 Stearate, Dimethicone, Isoamyl Laurate, Hydrogenated Vegetable Oil, Hydrogenated Soybean Oil, Butylene Glycol, Sodium Hyaluronate, Copper Tripeptide-1, Phosphatidylcholine, Acetyl Hexapeptide-8, Acetyl Tetrapeptide-11, Acetyl Tetrapeptide-9, Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, Dimethyl MEA, Tetrahexyldecyl Ascorbate, Tyrosine, Hydro- lyzed Myrtus Communis Leaf Extract, Rosmarinus Officinalis (Rosemary) Leaf Extract, Polysorbate-20, Dimethyl Isosorbide, Polysilicone-11, Phenoxyethanol, Petrolatum, Hydrogenated Olive Oil, Caprylyl Glycol, Coco-Glucoside, Hydrogenated Jojoba Oil, Echium Plantagineum Seed Oil, Citric Acid, Glycolic Acid, Helianthus Annuus (Sunflower) Seed Oil, Glycine Soja (Soybean) Lipids, Carbomer, Disodium EDTA, Phytosterols, Ethylhexylglycerin

In short, research studies are looking at new ways to lower the incidence of a second heart attack or stroke by targeting underlying conditions with new medications and new methods of treatment
Oral glutathione shows minimal bioavailability unless stabilized or liposomal